Tech Company Financing Transactions
Tacere Therapeutics Funding Round
On 10/12/2006, Tacere Therapeutics received financing from Hokkaido Venture Capital.
Transaction Overview
Company Name
Announced On
10/12/2006
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
Proceeds Purpose
With help of this funding, Company will established operations and resumed preclinical development of TT-033i, its lead candidate for the treatment of Hepatitis C (HCV).
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
5941 Optical Court
San Jose, CA 95138
USA
San Jose, CA 95138
USA
Phone
Website
Email Address
Overview
Tacere Therapeutics, Inc. specializes in the development of novel therapeutics for the treatment of serious infectious diseases such as Hepatitis C (HCV). Combining expertise in RNA interference (RNAi), gene medicine, and novel biologicals, Tacere possesses proprietary skill in the identification and development of RNAi therapeutics.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Sara Hall
Chief Financial Officer
Michael Catelani
Founder
Amit Kumar
Founder
John Monahan
Browse more venture capital transactions:
Prev: 10/10/2006: Achaogen venture capital transaction
Next: 10/12/2006: Morphotek venture capital transaction
Share this article
Where The Data Comes From
We document all VC transactions involving tech companies. VC investment data records reported here are derived from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs